Welcome to our dedicated page for LAVA Therapeutics N.V. news (Ticker: LVTX), a resource for investors and traders seeking the latest updates and insights on LAVA Therapeutics N.V. stock.
LAVA Therapeutics N.V. (LVTX) news coverage on this page centers on the company’s evolution as a clinical-stage immuno-oncology developer and its corporate transition following an acquisition by XOMA Royalty Corporation. Company press releases and SEC-linked announcements describe how LAVA advanced its proprietary Gammabody® platform of bispecific gamma-delta T cell engagers, while also undertaking restructuring measures and a strategic review that ultimately led to a tender offer and change of control.
Readers can follow updates related to LAVA’s pipeline programs, including the internal candidate LAVA‑1266 for CD123+ hematologic malignancies and partnered Phase 1 programs JNJ‑89853413 with Johnson & Johnson and PF‑08046052 with Pfizer Inc. News items detail clinical trial progress, portfolio reprioritization, and decisions to discontinue earlier programs such as LAVA‑1207 and LAVA‑051. These releases provide insight into how the company focused its resources on select assets while maintaining key collaborations.
Another major theme in LVTX news is corporate and capital structure events. LAVA announced an evaluation of strategic options, workforce reductions, closure of Netherlands operations, and a waiver of an Innovation Credit repayment obligation from the Netherlands Enterprise Agency (RVO). Subsequent news and 8‑K references document the share purchase agreement with XOMA Royalty Corporation, amendments to the offer terms, shareholder approvals at an extraordinary general meeting, and the successful tender of a large majority of outstanding shares.
For investors researching LVTX historically, this news stream provides context on both the scientific direction of LAVA’s Gammabody® platform and the sequence of events that resulted in LAVA becoming a majority-owned subsidiary of XOMA Royalty Corporation and delisting from the Nasdaq Global Select Market. Bookmark this page to access archived announcements, transaction milestones, and program updates associated with the former LVTX listing.
LAVA Therapeutics (Nasdaq: LVTX) announced that 22,877,463 common shares — about 87% of outstanding shares — were validly tendered and not withdrawn by the initial offer deadline of one minute after 11:59 p.m. ET on November 12, 2025.
The minimum tender condition for XOMA Royalty Corporation's acquisition offer has been satisfied and tendered shares are expected to be accepted for payment on or about November 13, 2025. A subsequent offering period runs through one minute after 11:59 p.m. ET on November 20, 2025 (shares tendered then cannot be withdrawn).
LAVA expects its Nasdaq trading to be suspended prior to market open on or about November 21, 2025, and expects Nasdaq to file a removal notification with the SEC on or about November 24, 2025. Completion remains subject to conditions in XOMA Royalty's Schedule TO.
LAVA Therapeutics (NASDAQ: LVTX) reminded shareholders to tender shares for the proposed sale to XOMA Royalty (NASDAQ: XOMA) before the Offer expiration at one minute after 11:59 p.m. ET on November 12, 2025. XOMA and LAVA entered a share purchase agreement on August 4, 2025, and XOMA extended its Offer on October 17, 2025.
The LAVA Board unanimously recommends tendering. The notice warns that if the required shares are not tendered the Offer cannot close, potentially exposing shareholders to liquidation with proceeds likely lower than the Offer cash consideration and to a possible share-price decline. Instructions and broker contact details are provided for tendering and questions.
LAVA Therapeutics (NASDAQ: LVTX) has announced the cancellation and rescheduling of its Extraordinary General Meeting (EGM) from September 30, 2025, to early November 2025. This decision relates to the company's pending acquisition by XOMA Royalty Corporation.
The postponement will allow additional time to continue discussions regarding transaction terms, specifically focusing on LAVA's estimated cash forecast and shareholder consideration. Both companies remain committed to completing the acquisition in Q4 2025. Previously cast shareholder votes will not be counted, and shareholders will need to recast their votes for the reconvened EGM.
LAVA Therapeutics (NASDAQ: LVTX) has announced significant developments in Q2 2025, headlined by a definitive agreement to be acquired by XOMA Royalty Corporation. The acquisition terms include $1.16-$1.24 per share in cash, plus contingent value rights tied to LAVA's partnered and unpartnered programs, with closing expected in Q4 2025.
The company reported Q2 2025 financial results with cash position of $56.2 million as of June 30, 2025, down from $76.6 million at year-end 2024. Net loss increased to $8.6 million ($0.32 per share) compared to $8.3 million ($0.31 per share) in Q2 2024. Additionally, LAVA announced the discontinuation of its LAVA-1266 program for acute myeloid leukemia and myelodysplastic syndrome.
Two partnered programs continue to progress: J&J's JNJ-89853413 in Phase 1 trials for AML/MDS, and Pfizer's PF08046052 for advanced solid tumors.
LAVA Therapeutics (NASDAQ: LVTX) has secured a full waiver for its $5.1 million repayment obligation from the Netherlands Enterprise Agency (RVO) related to an Innovation Credit granted in 2019. The waiver, which eliminates outstanding debt, strengthens the company's balance sheet as part of its ongoing strategic review and cost optimization initiatives.
The Innovation Credit was originally awarded for the development of LAVA-051, with certain project assets and IP pledged as guarantee. The RVO program provides interest-bearing loans to support innovative program development according to specific criteria.
LAVA Therapeutics (NASDAQ: LVTX) reported Q4 and full-year 2024 financial results, announcing a strategic restructuring including a 30% workforce reduction. The company achieved key milestones with a $5.0 million payment from Johnson & Johnson in Q4 2024 and a $7.0 million milestone payment from Pfizer in Q1 2024.
Financial highlights include a cash position of $76.6 million as of December 31, 2024, expected to fund operations into 2027. Revenue increased to $12.0 million for FY2024, up from $6.8 million in 2023. Net loss improved to $25.1 million ($0.94 per share) in 2024 from $41.9 million ($1.57 per share) in 2023.
The company is progressing with its LAVA-1266 Phase 1 clinical trial for acute myeloid leukemia and myelodysplastic syndrome, currently enrolling patients at the second dose level. Partner programs with J&J and Pfizer are also advancing in Phase 1 trials.
LAVA Therapeutics (NASDAQ: LVTX) has initiated a strategic review process to maximize shareholder value while implementing cost-cutting measures including a 30% workforce reduction. The clinical-stage immuno-oncology company, focused on its proprietary Gammabody® platform of bispecific gamma delta T cell engagers, has retained a financial advisor to support this evaluation.
Despite the restructuring, LAVA will continue enrolling patients in its Phase 1 clinical study of LAVA-1266 for hematologic malignancies, including acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), while supporting partnerships with Pfizer and Johnson and Johnson.
The company is exploring various strategic options including in-licensing assets, sale, licensing agreements, mergers, or acquisitions. The workforce reduction is expected to incur approximately $0.5 million in one-time costs primarily in Q1 2025. As of December 31, 2024, LAVA reported $76.6 million in cash, cash equivalents, and investments (unaudited).
LAVA Therapeutics (NASDAQ: LVTX) has announced the dosing of the first patient in its Phase 1 clinical trial of LAVA-1266, a CD123-targeted Gammabody® bispecific gamma delta T cell engager. The study focuses on treating hematologic cancers, specifically acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
The first-in-human study is being conducted in Australia, evaluating LAVA-1266's safety, pharmacokinetics, pharmacodynamic properties, and potential activity. The company expects to release initial Phase 1 data by year-end 2025. Preclinical models demonstrated tumor cell lysis with off-target effects, suggesting potential advantages over earlier CD123-targeted therapies that were by on-target, off-tumor toxicity, cytokine release syndrome, and capillary leak syndrome.
LAVA Therapeutics announced a strategic pipeline reprioritization focusing on LAVA-1266 for hematologic malignancies, while discontinuing LAVA-1207 development. The company will continue supporting partnered programs with Pfizer and Johnson & Johnson. Key Q4 developments include initiation of LAVA-1266 Phase 1 trial and a $5.0M milestone payment from J&J.
Financial highlights: Cash position of $78.9M as of September 30, 2024, with runway extended into 2027. Q3 2024 showed net losses of $12.3M ($0.46 per share) compared to $8.8M ($0.34 per share) in Q3 2023. Research and development expenses increased to $8.5M from $7.9M year-over-year.